Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
304 studies found for:    "Adenocarcinoma of lung"
Show Display Options
Download search resultsDownload the search results for:
"Adenocarcinoma of lung" (304 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Recruiting Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma
Condition: Adenocarcinoma of Lung
Interventions: Drug: recombinant human endostatin;   Drug: pemetrexed plus cisplatin or carboplatin
2 Active, not recruiting The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR
Condition: Adenocarcinoma of Lung
Interventions: Biological: Cytokine-Induced Killer Cells;   Drug: Apatinib
3 Recruiting Circulating Tumor DNA (ctDNA) as a Prognostic Tool in Patients With Advanced Lung Adenocarcinoma
Condition: Adenocarcinoma of Lung (Disorder)
Intervention: Genetic: Sequencing of ctDNA in plasma
4 Active, not recruiting Molecular Analysis of 150 Lung Adenocarcinoma
Condition: Lung Adenocarcinoma
Intervention: Genetic: Sequencing
5 Unknown  Expression of AMP-activated Protein Kinase (AMPK) Protein in Lung Adenocarcinoma
Condition: Lung Adenocarcinoma
Intervention:
6 Unknown  Study of Early-stage Lung Adenocarcinoma for Early Detection and Effective Treatment Strategy
Condition: Lung Adenocarcinoma
Intervention: Other: CT, PET, copy number alteration
7 Terminated NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma
Conditions: Adenocarcinoma of Lung Stage IIIB;   Adenocarcinoma of Lung Stage IV
Intervention: Drug: NOV120101 (Poziotinib)
8 Unknown  The Use of CT Perfusion to Determine the Normalization Window Period in the Treatment of Advanced Primary Lung Adenocarcinoma With Endostar
Condition: Advanced Primary Lung Adenocarcinoma
Intervention: Drug: endostar
9 Not yet recruiting Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma
Condition: Lung Adenocarcinoma
Intervention: Drug: Erlotinib, Pemetrexed
10 Recruiting Pemetrexed and Platinum Use in the Neoadjuvant Setting for Resectable Stage II and IIIA Lung Adenocarcinoma
Condition: Lung Adenocarcinoma
Interventions: Drug: Pemetrexed;   Drug: Cisplatin
11 Recruiting Chemoresistance and Involvement of the NOTCH Pathway in Patients With Lung Adenocarcinoma
Condition: Lung Adenocarcinoma
Intervention: Other: biopsies
12 Completed
Has Results
Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib
Condition: Lung Adenocarcinoma
Intervention: Drug: erlotinib with cetuximab
13 Recruiting A Study Examining Maintenance Avastin Monotherapy in Patients With Advanced Lung Adenocarcinoma
Condition: Lung Adenocarcinoma
Intervention:
14 Recruiting Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma
Condition: Lung Adenocarcinoma
Interventions: Biological: CIK;   Drug: chemotherapy
15 Not yet recruiting Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial
Condition: Lung Adenocarcinoma
Interventions: Drug: Pemetrexed plus carboplatin combined with gefitinib;   Drug: Gefitinib
16 Completed Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03)
Condition: Adenocarcinoma of the Lung
Interventions: Drug: Vintafolide;   Drug: Etarfolatide
17 Not yet recruiting Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFR
Condition: Lung Adenocarcinoma
Interventions: Drug: Apatinib (250 mg/d) + Docetaxel (60 mg/m2);   Drug: Apatinib (500 mg/d) + Docetaxel (60 mg/m2);   Drug: Apatinib (750 mg/d) + Docetaxel (60 mg/m2)
18 Completed A Safety and Efficacy Study of Farletuzumab in Subjects With Adenocarcinoma of the Lung
Condition: Adenocarcinoma of the Lung
Interventions: Biological: Farletuzumab;   Other: Placebo;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Pemetrexed;   Drug: Cisplatin
19 Recruiting A+C in Metastatic Lung Adenocarcinoma Cancer
Condition: Lung Adenocarcinoma Metastatic
Intervention: Drug: Crizotinib, bevacizumab
20 Recruiting Telomere Biology in Early Adenocarcinoma of the Lung
Conditions: Adenocarcinoma of the Lung;   Adenocarcinoma, Bronchiolo-Alveolar
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.